NASDAQ:KNTE Kinnate Biopharma (KNTE) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free knte Stock Alerts $2.65 -0.01 (-0.38%) (As of 04/2/2024) Add Compare Share Share Today's Range$2.64▼$2.6750-Day Range$2.43▼$2.6652-Week Range$1.04▼$7.18Volume2.81 million shsAverage Volume418,678 shsMarket Capitalization$125.13 millionP/E RatioN/ADividend YieldN/APrice Target$8.15 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Kinnate Biopharma alerts: Email Address Kinnate Biopharma MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside207.5% Upside$8.15 Price TargetShort InterestHealthy2.01% of Float Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.51) to ($1.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.37 out of 5 starsMedical Sector118th out of 916 stocksBiotechnology Industry3rd out of 26 stocks 3.0 Analyst's Opinion Consensus RatingKinnate Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageKinnate Biopharma has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.01% of the float of Kinnate Biopharma has been sold short.Short Interest Ratio / Days to CoverKinnate Biopharma has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kinnate Biopharma has recently decreased by 43.56%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKinnate Biopharma does not currently pay a dividend.Dividend GrowthKinnate Biopharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKinnate Biopharma has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Kinnate Biopharma is -0.81. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Kinnate Biopharma this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for KNTE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kinnate Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders41.70% of the stock of Kinnate Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.89% of the stock of Kinnate Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Kinnate Biopharma are expected to grow in the coming year, from ($2.51) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kinnate Biopharma is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kinnate Biopharma is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKinnate Biopharma has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Kinnate Biopharma Stock (NASDAQ:KNTE)Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.Read More KNTE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KNTE Stock News HeadlinesApril 26, 2024 | americanbankingnews.comKinnate Biopharma Inc. (NASDAQ:KNTE) Given Consensus Recommendation of "Hold" by AnalystsApril 5, 2024 | seekingalpha.comKNTE Kinnate Biopharma Inc.April 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.March 13, 2024 | businesswire.comKINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEMarch 1, 2024 | msn.comKinnate Biopharma sells rights of exarafenib to Pierre Fabre laboratoriesMarch 1, 2024 | markets.businessinsider.comKinnate Biopharma Sells Exarafenib To Pierre Fabre Laboratories - Quick FactsMarch 1, 2024 | prnewswire.comKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesMarch 1, 2024 | globenewswire.comKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre LaboratoriesApril 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.February 19, 2024 | businesswire.comKINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEFebruary 17, 2024 | realmoney.thestreet.comKinnate Biopharma just downgraded at William Blair, here's whyFebruary 17, 2024 | finance.yahoo.comPrivate equity firms who hold 45% of Kinnate Biopharma Inc. (NASDAQ:KNTE) gained 11%, institutions profited as wellFebruary 16, 2024 | prnewswire.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.February 16, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMAFebruary 16, 2024 | businesswire.comKNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to ShareholdersFebruary 16, 2024 | businesswire.comKNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to ShareholdersFebruary 16, 2024 | finance.yahoo.comKinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per ShareFebruary 16, 2024 | globenewswire.comKinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per ShareDecember 12, 2023 | seekingalpha.comKinnate Biopharma: Righting The Ship, But Still Not The Right Time (Rating Upgrade)November 24, 2023 | finance.yahoo.comKinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist InvestorsNovember 15, 2023 | msn.comWhy is Cancer-Focused Kinnate Biopharma Stock Trading Higher Today?November 15, 2023 | finance.yahoo.comOrbiMed Advisors LLC Reduces Stake in Kinnate Biopharma IncNovember 9, 2023 | finance.yahoo.comKinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesOctober 4, 2023 | theglobeandmail.comInstrument Name Kinnate Biopharma Inc Instrument Symbol (KNTE-Q)October 3, 2023 | finance.yahoo.comKinnate Biopharma (KNTE) Falls 40% in a Month: Here's WhySeptember 20, 2023 | msn.comJefferies Maintains Kinnate Biopharma (KNTE) Buy RecommendationSeptember 19, 2023 | msn.comBay Area biotech company Kinnate to lay off 70% of workforceSee More Headlines Receive KNTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/11/2023Today4/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:KNTE CUSIPN/A CIK1797768 Webwww.kinnate.com Phone858-299-4699FaxN/AEmployees84Year FoundedN/APrice Target and Rating Average Stock Price Target$8.15 High Stock Price Target$24.00 Low Stock Price Target$2.00 Potential Upside/Downside+207.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.31% Return on Assets-54.72% Debt Debt-to-Equity RatioN/A Current Ratio10.80 Quick Ratio10.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.06 per share Price / Book0.52Miscellaneous Outstanding Shares47,220,000Free Float27,532,000Market Cap$125.13 million OptionableOptionable Beta1.38 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Nima Farzan M.B.A. (Age 48)President, CEO & Director Comp: $891.95kMs. Neha Krishnamohan (Age 36)CFO, Principal Accounting Officer and Executive VP of Corporate Development Comp: $548.95kMr. Mark A. Meltz (Age 50)COO, General Counsel, Treasurer & Secretary Comp: $671.86kDr. Richard Thomas Williams MBBS (Age 55)Ph.D., Chief Medical Officer Dr. Robert Kania Ph.D.Senior Vice President of ResearchKey CompetitorsNGM BiopharmaceuticalsNASDAQ:NGMLianBioNASDAQ:LIANInotivNASDAQ:NOTVKaryopharm TherapeuticsNASDAQ:KPTICardiol TherapeuticsNASDAQ:CRDLView All CompetitorsInsiders & InstitutionsEquitec Proprietary Markets LLCBought 98,500 shares on 4/26/2024Ownership: 0.000%BML Capital Management LLCBought 30,641 shares on 4/23/2024Ownership: 1.056%Deltec Asset Management LLCBought 1,039,800 shares on 4/17/2024Ownership: 2.202%Pale Fire Capital SEBought 150,381 shares on 2/14/2024Ownership: 0.468%Dynamic Technology Lab Private LtdBought 13,891 shares on 2/9/2024Ownership: 0.029%View All Insider TransactionsView All Institutional Transactions KNTE Stock Analysis - Frequently Asked Questions Should I buy or sell Kinnate Biopharma stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kinnate Biopharma in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" KNTE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KNTE, but not buy additional shares or sell existing shares. View KNTE analyst ratings or view top-rated stocks. What is Kinnate Biopharma's stock price target for 2024? 5 brokerages have issued 12 month target prices for Kinnate Biopharma's stock. Their KNTE share price targets range from $2.00 to $24.00. On average, they expect the company's stock price to reach $8.15 in the next year. This suggests a possible upside of 207.5% from the stock's current price. View analysts price targets for KNTE or view top-rated stocks among Wall Street analysts. How have KNTE shares performed in 2024? Kinnate Biopharma's stock was trading at $2.37 on January 1st, 2024. Since then, KNTE shares have increased by 11.8% and is now trading at $2.65. View the best growth stocks for 2024 here. When is Kinnate Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our KNTE earnings forecast. How were Kinnate Biopharma's earnings last quarter? Kinnate Biopharma Inc. (NASDAQ:KNTE) issued its quarterly earnings data on Thursday, May, 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.73). When did Kinnate Biopharma IPO? Kinnate Biopharma (KNTE) raised $170 million in an IPO on Thursday, December 3rd 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO. Who are Kinnate Biopharma's major shareholders? Kinnate Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Deltec Asset Management LLC (2.20%), BML Capital Management LLC (1.06%) and Equitec Proprietary Markets LLC (0.00%). Insiders that own company stock include Carl L Gordon, James B Tananbaum, Orbimed Advisors Llc and Richard Thomas Williams. View institutional ownership trends. How do I buy shares of Kinnate Biopharma? Shares of KNTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KNTE) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressGreat Crypto BullWeiss RatingsJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kinnate Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
